Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21146017 | 0.83 | USP2 (0.45) | ALDH1A1 | |
| SCHEMBL19701967 | 0.75 | TSHR (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3GRM5 | |
| SCHEMBL21145995 | 0.73 | F2R (0.36) | TSHR | |
| SCHEMBL21738162 | 0.73 | HRH3 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL14706990 | 0.72 | GPR119 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL30091958 | 0.72 | CHRNA4 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3GRM5 | |
| SCHEMBL21145998 | 0.71 | HRH3 (0.34) | CYP2D6 | |
| SCHEMBL24117892 | 0.71 | — | — | |
| SCHEMBL25143517 | 0.70 | — | — | |
| SCHEMBL21593873 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247965-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2019118358-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | CHRNB2 3007/4885CHRNA4 3799/4885CHRNB4 3388/4885 |
| US-11247965-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | CHRNB2 3007/4885CHRNA4 3799/4885CHRNB4 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.